Cardiff Oncology Inc Aktie News

Cardiff Oncology is a speculative buy, driven by the potential of onvansertib as a first-in-class PLK1 inhibitor for first-line RAS-mutated mCRC. CRDF's Q1 2026 data readout for onvansertib is a pivotal catalyst, with positive results potentially unlocking blockbuster sales and significant share price appreciation. Key risks include clinical trial execution, capital needs, and heavy reliance on...

Cardiff Oncology receives a 'Buy' rating, driven by promising clinical data and strategic leadership for long-term investors. CRDF's lead candidate, onvansertib, shows strong efficacy and safety in Phase 2 trials for RAS-mutated metastatic colorectal and triple-negative breast cancers. Despite competition and clinical-stage risks, onvansertib's unique PLK1 inhibition mechanism offers breakthrou...

SAN DIEGO, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in two upcoming investor conferences in October 2025.

SAN DIEGO, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in the three upcoming investor conferences in September 2025. Details of the events can be found below.

Cardiff Oncology (CRDF) Q2 Loss Down 19%

Onvansertib continues to show dose-dependent activity in KRAS-mutated mCRC, with response rates improving up to 49% in the high-dose arm. Recent data are less dramatic than early interim results, reflecting typical regression to the mean and leaving some questions unanswered until the next update in Q1 2026. CRDF's cash position is stable for now, but a future financing need is likely as the co...

– Trial demonstrates 49% confirmed ORR in the 30mg onvansertib dose arm versus 30% confirmed ORR in the control arm in intent-to-treat population (N=110) –

Cardiff Oncology's recent trial data readout delay has unnerved the market, but I see this as a potential buying opportunity for speculative investors. Leadership change is not a major risk factor. The new CMO's pedigree suggests confidence in the company's prospects ahead of the catalyst. The delay could suggest an attempt to improve poor data, or an ability to add to already strong data by wa...